Nektar Therapeutics
NKTR
£17.71
Share price
-5.40%
Change (1 day)
1,574.34%
Change (1 year)
Categories
Nektar Therapeutics (NKTR) - Cash on Hand
Cash on Hand as of March 2025 : £0.16 Billion
According to Nektar Therapeutics
's latest financial reports the company has £0.16 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Nektar Therapeutics - Cash on Hand chart (from 1996 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | £0.20 B | -14.66% |
| 2023-12-31 | £0.23 B | -42.91% |
| 2022-12-31 | £0.41 B | -23.23% |
| 2021-12-31 | £0.54 B | -30.21% |
| 2020-12-31 | £0.77 B | -22.89% |
| 2019-12-31 | £1.01 B | -3.96% |
| 2018-12-31 | £1.05 B | 380.11% |
| 2017-12-31 | £0.21 B | -30.52% |
| 2016-12-31 | £0.31 B | 51.26% |
| 2015-12-31 | £0.20 B | 36.48% |
| 2014-12-31 | £0.15 B | 6.3% |
| 2013-12-31 | £0.14 B | -16.21% |
| 2012-12-31 | £0.17 B | 10.53% |
| 2011-12-31 | £0.15 B | -24.18% |
| 2010-12-31 | £0.20 B | -16.41% |
| 2009-12-31 | £0.24 B | -5.32% |
| 2008-12-31 | £0.25 B | 6.5% |
| 2007-12-31 | £0.24 B | 3.7% |
| 2006-12-31 | £0.23 B | -15.21% |
| 2005-12-31 | £0.27 B | 26.6% |
| 2004-12-31 | £0.21 B | 36.44% |
| 2003-12-31 | £0.15 B | -12.81% |
| 2002-12-31 | £0.18 B | -22.8% |
| 2001-12-31 | £0.23 B | -26.89% |
| 2000-12-31 | £0.32 B | 279.85% |
| 1999-12-31 | £85.52 M | 71.61% |
| 1998-12-31 | £49.83 M | -18.28% |
| 1997-12-31 | £60.98 M | 461.38% |
| 1996-12-31 | £10.86 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | £6.59 B | 3,929.60% | 🇺🇸 USA |
 Pfizer PFE | £12.96 B | 7,820.16% | 🇺🇸 USA |
 Merck MRK | £6.90 B | 4,120.79% | 🇺🇸 USA |
 Richardson Electronics RELL | £27.45 M | -83.23% | 🇺🇸 USA |
 AstraZeneca AZN | £4.03 B | 2,367.62% | 🇬🇧 UK |
 Baxter BAX | £1.71 B | 949.25% | 🇺🇸 USA |
 Alkermes ALKS | £0.66 B | 304.34% | 🇮🇪 Ireland |
 Johnson & Johnson JNJ | £29.03 B | 17,638.03% | 🇺🇸 USA |